CAS No. :	139110-80-8
Formula :	C₁₂H₂₀N₄O₇
M.W :	332.31
SMILES Code :	O=C(C1=C[C@H](NC(N)=N)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1)O
Synonyms :	GG 167; GR 121167X
MDL No. :	MFCD00866966
InChI Key :	ARAIBEBZBOPLMB-UFGQHTETSA-N
Pubchem ID :	60855

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Madin-Darby canine kidney cells	8.5 to 14.0 µM (EC50)	18 hours	Zanamivir inhibited the replication of H6N1 and H9N2 influenza viruses in MDCK cells, with EC50 ranging from 8.5 to 14.0 μM.	Antimicrob Agents Chemother. 2001 Apr;45(4):1216-24.
Madin-Darby canine kidney cells (MDCK)	0.418 ng/ml (1.254 nM)	24 hours	Evaluate the inhibitory effect of Zanamivir on A/Hong Kong (H275Y) virus, results showed the virus was susceptible to Zanamivir	Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53.
Calu-3 cells	35 μg/mL	48 hours	Inhibition of H1N1 virus replication	Int J Mol Sci. 2022 Dec 30;24(1):678.
A549 cells	35 μg/mL	48-72 hours	Inhibition of H1N1 virus replication	Int J Mol Sci. 2022 Dec 30;24(1):678.
MDCK cells	35 μg/mL	48-72 hours	Inhibition of H1N1 virus replication	Int J Mol Sci. 2022 Dec 30;24(1):678.

Mice and ferrets	Influenza virus infection model	Intranasal administration	0.028 µmol/kg	Dosing at 6, 24, and 48 hours post-infection, lasting for 72 hours	To evaluate the inhibitory effect of polymer-attached Zanamivir (5a) on influenza virus infection in vivo. Results showed that 5a was more effective than small-molecule Zanamivir (1), reducing viral load by 190-fold in mice and 30-fold in ferrets.	Pharm Res. 2014 Feb;31(2):466-74
BALB/c mice	Avian influenza virus infection model	Intranasal administration	10, 50, and 100 mg/kg	Twice daily for 5 days	Zanamivir significantly reduced virus titers in the lungs and completely blocked the spread of virus to the brain, increasing the mean survival day and the number of survivors infected with H6N1 and H5N1 viruses.	Antimicrob Agents Chemother. 2001 Apr;45(4):1216-24.
C57BL/6 mice	H1N1 infection model	Intranasal administration	35 μg/mL	Once daily for seven days	Prevented weight loss, increased survival rate, and improved lung fibrosis	Int J Mol Sci. 2022 Dec 30;24(1):678.
DBA/1J mice	Collagen-induced arthritis (CIA)	Intraperitoneal injection	50 mg/kg and 100 mg/kg	Once daily, starting two days before immunization until the end of the experiment	Zanamivir significantly ameliorated the clinical symptoms of CIA, delayed disease onset, and reduced the numbers of B-lineage cells, accompanied by inhibition of the humoral immune response.	Int J Mol Sci. 2021 Jan 31;22(3):1428

NCT00705406	Acute, Uncomplicated Human Inf... More >>luenza Less <<	Phase 2	Completed	-	-
NCT00958776	Cough Sore Th... More >>roat Nasal Congestion Headache Fever Seasonal Influenza Less <<	Phase 3	Terminated(This study was term... More >>inated for futility) Less <<	-	-
NCT00705406	-		Completed	-	-
NCT01793883	Influenza	Phase 2	Completed	-	-
NCT01052480	-		Completed	-	-
NCT00958776	-		Terminated(This study was term... More >>inated for futility) Less <<	-	-
NCT01052480	Influenza A I... More >>nfluenza B Less <<	Phase 2	Completed	-	-
NCT02022761	Asthma	Phase 1	Completed	-	United Kingdom ... More >> Respiratory Clinical Trials London, United Kingdom, W1G 8HU Less <<
NCT01793883	-		Completed	-	-
NCT01506583	-		Unknown	July 2012	United States, Alabama ... More >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35294 Contact: David Kimberlin, M.D. 205-934-5316 dkimberlin@peds.uab.edu Contact: Dusty Giles, R.N. 205-934-7807 dgiles@peds.uab.edu Principal Investigator: David Kimberlin, M.D. United States, Illinois Northwestern University Feinberg School of Medicine Recruiting Chicago, Illinois, United States, 61611 Contact: Mike Ison, M.S., M.D. 312-695-4186 mgison@northwestern.edu Principal Investigator: Mike Ison, M.S., M.D. United States, Maryland University of Maryland School of Medicine Completed Baltimore, Maryland, United States, 21201 Less <<
NCT01055990	Virus Diseases ... More >> Respiratory Tract Diseases Respiratory Tract Infections Influenza Orthomyxoviridae Infections Less <<	Phase 2	Unknown	May 2010	China, Shanghai ... More >> Shanghai Public Health Clinical Center Shanghai, Shanghai, China, 201508 Less <<
NCT00867139	Influenza	Phase 1 Phase 2	Completed	-	United States, Washington ... More >> Seattle Children's Seattle, Washington, United States, 98105 Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 Less <<
NCT02014649	Influenza	Phase 1 Phase 2	Terminated(Study was terminate... More >>d as per BARDA decision to terminate contract.) Less <<	-	-
NCT00640874	-		Withdrawn	-	Australia, New South Wales ... More >> St Vincent's Hospital Sydney, New South Wales, Australia, 2010 Prince of Wales Hospital Sydney, New South Wales, Australia, 2031 Westmead Hospital Sydney, New South Wales, Australia, 2145 Australia, Queensland Royal Brisbane Hospital Brisbane, Queensland, Australia, 4000 Australia, South Australia Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 Flinders Medical Centre Adelaide, South Australia, Australia, 5042 Australia, Victoria The Alfred Hospital Melbourne, Victoria, Australia, 3004 Australia, Western Australia Royal Perth Hospital Perth, Western Australia, Australia, 6000 Less <<
NCT00867139	-		Completed	-	-
NCT00640211	-		Withdrawn	-	Australia, New South Wales ... More >> St Vincent's Hospital Sydney, New South Wales, Australia, 2010 Prince of Wales Hospital Sydney, New South Wales, Australia, 2031 Westmead Hospital Sydney, New South Wales, Australia, 2145 Australia, Queensland Royal Brisbane Hospital Brisbane, Queensland, Australia, 4000 Australia, South Australia Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 Flinders Medical Centre Adelaide, South Australia, Australia, 5042 Australia, Victoria The Alfred Hospital Melbourne, Victoria, Australia, 3004 Australia, Western Australia Royal Perth Hospital Perth, Western Australia, Australia, 6000 Less <<
NCT03684044	Influenza	Phase 3	Recruiting	July 10, 2021	-
NCT01353768	-		Completed	-	-
NCT00979667	Upper Respiratory Tract Infect... More >>ion Influenza Less <<	Phase 3	Terminated(Decreased Influenza... More >> activity; thus decrease/no eligible patient to recruit) Less <<	-	China, Hong Kong ... More >> Shau Kei Wan Jockey Club Clinic Hong Kong, Hong Kong, China, 852 Hong Kong Fanling Family Medicine Centre Hong Kong, Hong Kong Sai Ying Pun Jockey Club General Outpatient Clinic Hong Kong, Hong Kong Less <<
NCT01156701	-		Completed	-	-
NCT01156701	-		Completed	-	-
NCT00980109	Influenza	Phase 4	Completed	-	Thailand ... More >> Faculty of Medicine Siriraj Hospital Bangkok, Bangkoknoi, Thailand, 10700 Hospital for Tropical Diseases Bangkok, Thailand, 10400 Less <<
NCT01353729	Influenza, Human	Phase 1	Completed	-	United States, Texas ... More >> GSK Investigational Site Austin, Texas, United States, 78744 Less <<
NCT00989404	Influenza A Virus, H1N1 Subtyp... More >>e Less <<	Phase 1	Completed	-	United States, Minnesota ... More >> GSK Investigational Site Minneapolis, Minnesota, United States, 55404 Less <<
NCT00830323	Influenza A Infection	Phase 2	Terminated	August 2009	France ... More >> Hospices civils de Lyon Lyon, France Less <<
NCT00921726	Influenza Vir... More >>us Diseases Less <<	Phase 1	Completed	-	Thailand ... More >> Mathidol University Salaya, Thailand, 73170 Less <<
NCT01459081	Influenza A Virus Infection ... More >> Influenza B Virus Infection Less <<	Phase 3	Completed	-	China ... More >> The Third Xiangya Hospital Of Central South University Changsha, China West China Hospital, Sichuan University Chengdu, China The First People's Hospital of Hangzhou Hangzhou, China The Affiliated Hospital of Inner Mongolia Medical College Huhehaote, China The First Affiliated Hospital of Nanchang University Nanchang, China The First Affiliated Hospital of Nanjing Medical University Nanjing, China Qingdao Municipal Hospital Qingdao, China Shanghai 6th People's Hospital Shanghai, China Shanghai Changzheng Hospital Shanghai, China ShengJing Hospital of China Medical University Shenyang, China Tangdu Hospital Affiliated to the Fourth Military Medical University Xi'an, China Northern Jiangsu People's Hospital Yangzhou, China Less <<
NCT01199744	-		Completed	-	-
NCT00540501	Healthy Subjects	Phase 1	Withdrawn(Contract agreement n... More >>ot reached) Less <<	October 2007	-
NCT01199744	-		Completed	-	-
NCT01014988	-		Completed	-	-
NCT01014988	Influenza, Human	Phase 2	Completed	-	-
NCT00799760	Gastric Influenza	Phase 3	Terminated(Just Terminated for... More >> the end of the pandemia) Less <<	-	France ... More >> Centre Investigateur 155 Deulemont, France, 59000 Less <<
NCT00784784	-		Completed	-	-
NCT01462487	-		Completed	-	-
NCT01231620	Influenza, Human	Phase 3	Completed	-	-
NCT01231620	-		Completed	-	-
NCT01390792	-		Completed	-	-
NCT02377401	Influenza, Human	PHASE1	COMPLETED	2015-06-19	GSK Investigational Site, Shan... More >>ghai, 200030, China Less <<
NCT01527110	Influenza, Human	Phase 3	Completed	-	Japan ... More >> GSK Investigational Site Fukuoka, Japan, 816-0864 GSK Investigational Site Kanagawa, Japan, 247-8533 GSK Investigational Site Miyagi, Japan, 983-0824 GSK Investigational Site Miyagi, Japan, 985-8506 GSK Investigational Site Okayama, Japan, 700-8557 GSK Investigational Site Osaka, Japan, 581-0011 GSK Investigational Site Shizuoka, Japan, 432-8002 Less <<
NCT00784784	Influenza	Phase 3	Completed	-	Canada, Ontario ... More >> Mount Sinai Hospital Toronto, Ontario, Canada, M5G 1X5 Less <<
NCT01527110	-		Completed	-	-
NCT04494412	Influenza, Human\|Arthralgia	PHASE2	RECRUITING	2026-12-09	GSK Investigational Site, Nijm... More >>egen, 6525 GA, Netherlands\|GSK Investigational Site, Bydgoszcz, 85-168, Poland\|GSK Investigational Site, Esplugues De Llobregat. Barcelona, 08950, Spain\|GSK Investigational Site, Madrid, 28046, Spain\|GSK Investigational Site, Dundee, DD1 9SY, United Kingdom\|GSK Investigational Site, London, SW17 0QT, United Kingdom\|GSK Investigational Site, London, W2 1NY, United Kingdom Less <<
NCT04867707	Diabetes Mellitus, Type 2	PHASE2	COMPLETED	2024-10-18	University of Missouri, School... More >> of Medicine Clinical Research Center, Columbia, Missouri, 65212, United States Less <<

{[proInfo.proName]}

CAS No.: 139110-80-8

{[proInfo.proName]}

CAS No.: 139110-80-8

Alternative Products

Product Details of Zanamivir

Safety of Zanamivir

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed